Position of the Transparency Council – Vabinxo (valsartan + indapamide)
At its meeting on 9 December 2024, the Transparency Council adopted position No. 142/2024 on the evaluation of the drug Vabinxo (valsartan + indapamide) for the indication: treatment of spontaneous hypertension